Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prafnosbart
- Development stage
- Phase 1
- Lead developer
- Daiichi Sankyo
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
DS-6016a (prafnosbart) is a humanized IgG1-kappa monoclonal antibody that targets the activin A receptor type 1 (ACVR1, also known as ALK2). It was developed by Daiichi Sankyo and Saitama Medical University for the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification. In FOP, mutations in ACVR1/ALK2 lead to abnormal bone formation due to hyper-responsiveness to bone morphogenetic proteins (BMPs) and aberrant signaling via Activin A. By inhibiting ALK2, DS-6016a aims to block this pathological signaling pathway and prevent disease progression. The drug has been evaluated in phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy volunteers[1][5][7].
- Other names
- Anti ALK2 monoclonal antibody - Daiichi Sankyo/Saitama Medical UniversityAnti-ALK2 antibody - Daiichi Sankyo/Saitama Medical UniversityPrafnosbart
02
Targets
ACVR1 (Activin receptor type I)
Beyond the preview
Go deeper on prafnosbart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prafnosbart.